MedPath

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

Phase 3
Conditions
HIV Infections
Registration Number
NCT00007436
Lead Sponsor
Gilead Sciences
Brief Summary

The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.

Detailed Description

Patients take tenofovir DF in combination with other antiretrovirals.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (19)

East Bay AIDS Ctr

🇺🇸

Berkeley, California, United States

Tower ID Med Associates

🇺🇸

Los Angeles, California, United States

Pacific Horizons Med Group

🇺🇸

San Francisco, California, United States

Harbor - UCLA Med Ctr

🇺🇸

Torrance, California, United States

Univ of Colorado / Health Science Ctr

🇺🇸

Denver, Colorado, United States

Physicans Home Service

🇺🇸

Washington, District of Columbia, United States

Steinhart Medical Associates

🇺🇸

Miami, Florida, United States

Dr Gerald Pierone Jr

🇺🇸

Vero Beach, Florida, United States

Northstar Med Clinic

🇺🇸

Chicago, Illinois, United States

CRI New England

🇺🇸

Brookline, Massachusetts, United States

Scroll for more (9 remaining)
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.